Welcome to our dedicated page for Galmed Pharmaceu SEC filings (Ticker: GLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Galmed Pharmaceuticals鈥� latest 10-K can feel like parsing a clinical journal鈥攈undreds of pages on Aramchol trials, cash runway projections, and patent timelines. If you have ever wondered 鈥淕almed Pharmaceuticals SEC filings explained simply鈥� or hunted through footnotes for the next NASH milestone, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries highlight exactly where the Phase III Aramchol data sits, flag R&D expense trends, and decode risk factors鈥攁ll as soon as each document hits EDGAR. Whether you need a Galmed Pharmaceuticals quarterly earnings report 10-Q filing or a sudden Galmed Pharmaceuticals 8-K material events explained, real-time alerts surface the key numbers and language investors track.
Every filing type is covered:
- 10-K / annual report鈥攃ash runway and pipeline outlook, now in a 鈥淕almed Pharmaceuticals annual report 10-K simplified鈥� format.
- 10-Q / quarterly earnings鈥攖rial spend and dilution risk, complete with 鈥淕almed Pharmaceuticals earnings report filing analysis鈥�.
- Form 4 insider trades鈥攊nstant emails on 鈥淕almed Pharmaceuticals Form 4 insider transactions real-time鈥� so you can see when executives buy more shares ahead of readouts.
- Proxy statement鈥攃lear tables on 鈥淕almed Pharmaceuticals proxy statement executive compensation鈥� linked to clinical milestones.
Need practical use cases? Monitor 鈥淕almed Pharmaceuticals executive stock transactions Form 4鈥�, compare R&D burn across quarters, or assess dilution clauses before the next raise鈥�all in one dashboard. Start understanding Galmed filings with AI clarity and make decisions faster than ever.
CVI Investments, Inc. and Heights Capital Management, Inc. disclosed a beneficial position in Galmed Pharmaceuticals Ltd. consisting of 173,333 ordinary shares, equal to 7.1% of the class based on 2,258,034 shares outstanding as reported by the company as of March 31, 2025. The reported position represents shares issuable upon exercise of warrants, and the warrants include an exercise limitation that prevents exercises that would push ownership above 9.99%. Heights Capital serves as investment manager to CVI and may have shared voting and dispositive power over the reported shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest.
FAQ
What is the current stock price of Galmed Pharmaceu (GLMD)?
What is the market cap of Galmed Pharmaceu (GLMD)?
